StockWatch
·

MYRIAD GENETICS INC Q3 FY25 Results

MYGNQ3 FY25 Results
Filing
MetricValue ($ M)Q2 FY25Q3 FY24
Revenue205.703.5%3.6%
Total Income205.703.5%3.6%
Expenditure229.0057.8%1.8%
PBT-26.2092.1%23.6%
Net Profit-27.4091.7%24.0%
OPM-11.33%1.95pp
NPM-13.32%2.96pp
EPS-0.2991.9%20.8%
View full financials

Myriad Genetics Reports Q3 2025 Revenue of $205.7 Million

04 May 2026 · 4 May, 8:20 am

Summary

Myriad Genetics announced its third quarter 2025 financial results, reporting revenue of $205.7 million, a 4% decrease year-over-year. However, excluding previously discussed headwinds, revenue was flat. Hereditary cancer testing revenue and volume grew by 3% and 11%, respectively. The company's GAAP net loss was $27.4 million, while adjusted EBITDA was $10.3 million. Myriad Genetics reaffirmed its financial guidance for the full year 2025 and entered a strategic collaboration with SOPHiA GENETICS.

Key Highlights

  1. 1

    Myriad Genetics reported third quarter 2025 revenue of $205.7 million, a decrease of 4% year-over-year.

  2. 2

    Hereditary cancer testing revenue in the third quarter of 2025 grew 3% year-over-year.

  3. 3

    Hereditary cancer testing volume increased by 11% year-over-year in the third quarter of 2025.

  4. 4

    The company's third quarter 2025 gross margin was 69.9%.

  5. 5

    Myriad Genetics' GAAP net loss for the third quarter of 2025 was $27.4 million, or $0.29 per share.

  6. 6

    Third quarter 2025 adjusted EBITDA was $10.3 million.

  7. 7

    Myriad Genetics entered a strategic collaboration with SOPHiA GENETICS to develop an innovative global liquid biopsy companion diagnostic testing solution.

Management Comments

S

Sam Raha

I am pleased with our solid results for the quarter, including stable year-over-year revenue performance excluding previously noted headwinds, and 13% year-over-year volume growth for our MyRisk hereditary cancer test. Our disciplined execution also enabled our gross margin to be among the best in the industry and again yielded positive adjusted EBITDA. We are executing on our updated strategy to accelerate profitable growth by focusing on the Cancer Care Continuum, including recently entering into a collaboration with SOPHiA GENETICS to provide Pharma customers with CDx development services using a leading liquid biopsy therapy selection assay. We also made changes to our organizational structure and capital deployment, and expect these actions to support us in improving customer experience, gaining market share, and reducing operating expenses as a percentage of revenue going forward.

Informational and educational content only. Not investment advice.